Sorry, you need to enable JavaScript to visit this website.

Treatment for Crohns's Disease (CD) & Ulcerative Colitis (UC) | STELARA® (ustekinumab) HCP

For the treatment of adult patients with moderately to severely active Crohn’s disease (CD) or ulcerative colitis (UC).

*In both the CD and UC studies, many patients achieved clinical remission at 1 year with STELARA®.

FAST

RAPID RESPONSE:
Clinical response† was achieved 
as early as Week 6 in CD and 
Week 8 in UC1

VIEW RESPONSE 
IN CD
VIEW RESPONSE 
IN UC

†In CD, clinical response was defined as reduction in CDAI score of ≥100 points or CDAI score of <150. In UC, clinical response was defined as a decrease from baseline in the modified Mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1.

LASTS

LASTING REMISSION:
Many patients achieved clinical remission‡ at 1 year in the CD and UC clinical trials. In CD, the majority of those patients remained in clinical remission at ≈5 years.§ In UC, the majority of those patients remained in symptomatic remissionII at ≈4 years1,2¶

VIEW REMISSION 
IN CD
VIEW REMISSION
IN UC

‡In CD, clinical remission was defined as a CDAI score of <150. In UC, clinical remission was defined as Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and Mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability).

§53% (68/128) of patients were in clinical remission at 1 year; of these patients, 59% (40/68) were in clinical remission at 5 years.

IISymptomatic remission was defined as a Mayo stool frequency subscore of 0 or 1 and a Mayo rectal bleeding subscore of 0.

45% (79/176) of patients were in clinical remission at 1 year; of these patients, 69% (53/77) were in symptomatic remission at 4 years.

PROVEN

SAFETY PROFILE:
The safety profile in CD and UC studies through 1 year was consistent with that seen in other approved indications1

VIEW SAFETY 
IN CD
VIEW SAFETY 
IN UC

Local Coverage

Commercial Formulary Coverage Look-up

Enter Your ZIP Code to View Coverage Results

Please enter zip code  

All information is subject to change. Actual benefits determined by health plan. We strongly recommend you call the health plan for its reimbursement policies. This information does not advise on or guarantee coverage or payment.

STELARA®—5 YEARS OF EFFICACY AND SAFETY DATA IN CROHN’S DISEASE (CD)

In the phase 3 clinical trials and open-label LTE1,2

LEARN ABOUT TREATING CD WITH STELARA®

STELARA®—4 YEARS OF EFFICACY AND SAFETY DATA IN ULCERATIVE COLITIS (UC)2

In the phase 3 clinical trials and open-label LTE

LEARN ABOUT TREATING UC WITH STELARA®

STELARA withMe is here to support your patients

STELARA withMe provides a range of dedicated support and resources to help make it easier for patients as they begin, and continue, their STELARA® treatment journey.

Visit stelarawithme.com/HCP

LEARN MORE

CD=Crohn’s disease; CDAI=Crohn's Disease Activity Index; FDA=Food and Drug Administration; HEMI=histo-endoscopic mucosal improvement; LTE=long-term extension; UC=ulcerative colitis.

†In CD, clinical response was defined as reduction in CDAI score of ≥100 points or CDAI score of <150. In UC, clinical response was defined as a decrease from baseline in the modified Mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1.

‡In CD, clinical remission was defined as a CDAI score of <150. In UC, clinical remission was defined as Mayo stool frequency subscore of 0 or 1, Mayo rectal bleeding subscore of 0, and Mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability).

References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.